SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Faeth Therapeutics entered into an at-the-market (ATM) offering agreement with TD Securities on June 18, 2026, authorizing the sale of up to $150 million in common stock shares, representing a classic dilutive equity issuance that signals potential capital needs and future shareholder dilution.
View raw filing on EDGAR →Automatic conversion of 24,435.594 shares of Series B Non-Voting Convertible Preferred Stock into 24,435,594 shares of Common Stock materially increased the outstanding share count to 25,778,754 shares, resulting in significant dilution to existing shareholders' ownership percentages and earnings per share.
View raw filing on EDGAR →Sagtec Global Limited issued 1,500,000 Class A Ordinary Shares to CEO and major shareholder Ng Chen Lok at US$1.04 per share (US$1.56 million aggregate) in a private placement of unregistered, restricted securities with no registration rights.
View raw filing on EDGAR →Globavend entered into a Standby Equity Purchase Agreement (SEPA) on June 16, 2026, with YA II PN, Ltd. for the purchase of up to $20 million of ordinary shares over 36 months. This is a committed equity financing arrangement where the company can draw down capital by issuing shares at a discount to market price (93–96% of VWAP), subject to registration. The structure and mechanics—discretionary advances, volume-weighted pricing, and a $20 million commitment—are characteristic of a PIPE-like dilutive equity issuance used to raise capital.
View raw filing on EDGAR →SS Innovations entered into an ATM Sales Agreement with Virtu Americas LLC on June 18, 2026, to sell up to $50 million of common stock through an "at the market offering" program. This is a classic dilutive equity issuance that would materially affect existing shareholders through potential dilution and is a significant capital-raising activity for the company.
View raw filing on EDGAR →The Company completed an unregistered private placement of 600,000 Class A Ordinary Shares to the Sponsor at $10.00 per share ($6 million gross proceeds) pursuant to Section 4(a)(2) of the Securities Act, simultaneously with the IPO closing. This is a material dilutive issuance typical of SPAC sponsor equity stakes.
View raw filing on EDGAR →IceCure completed a $5.5 million private placement of 1,833,334 ordinary shares plus Series D and E Warrants to a healthcare-focused institutional investor at $3.00 per share, issued under Section 4(a)(2) exemption.
View raw filing on EDGAR →The filing discloses a registered public offering of 38,333,333 shares of common stock (including full exercise of the underwriter's over-allotment option) generating approximately $63.25 million in gross proceeds. This is a material dilutive equity issuance that would significantly affect a reasonable investor's assessment of ownership dilution and the company's capital structure. The offering was conducted pursuant to an effective Form S-1 registration statement, making this a registered public offering rather than an unregistered private placement.
View raw filing on EDGAR →Item 3.02 discloses an unregistered private placement of a Pre-Funded Warrant to Tether issued on June 18, 2026 as consideration for transfer of 50% of a receivable under an existing loan. The warrant was issued without Securities Act registration under Section 4(a)(2) and Regulation D Rule 506(b) exemptions, representing a dilutive equity issuance to an accredited investor. This is a material capital structure event affecting shareholder equity.
View raw filing on EDGAR →The press release announces a private placement of $6.5 million in ordinary shares (or pre-funded warrants) and ordinary warrants to accredited and institutional investors under Section 4(a)(2) and Regulation D exemptions. This is an unregistered equity issuance that will dilute existing shareholders, with 1,857,143 ordinary shares and accompanying warrants being issued at $3.50 per share. The company explicitly states it has entered into definitive securities purchase agreements and expects closing on June 23, 2026.
View raw filing on EDGAR →Hyperscale Data entered into an At-the-Market (ATM) Issuance Sales Agreement on June 18, 2026, to sell up to $300 million of Class A common stock through Spartan Capital Securities. The offering is a registered equity issuance that will be dilutive to existing shareholders' ownership percentages and voting power, with proceeds earmarked for facility development, Bitcoin acquisition, and precious metals purchases.
View raw filing on EDGAR →CervoMed entered into a Securities Purchase Agreement for a registered direct offering of 2,500,000 shares of common stock at $4.00 per share, raising $10 million in gross proceeds. The offering includes placement agent warrants equal to 6.0% of shares issued and represents a material dilutive equity issuance to existing shareholders.
View raw filing on EDGAR →The Company issued 545,591 shares of common stock to Lind Global Asset Management in satisfaction of payment obligations under a $7.5 million senior secured convertible promissory note. The issuances occurred on June 17, 2026 and May 19, 2026, relying on Section 3(a)(9), Section 4(a)(2), and/or Regulation D exemptions. This is a dilutive equity issuance to an existing securityholder in connection with debt repayment obligations, which materially affects share count and ownership structure.
View raw filing on EDGAR →The 6-K discloses a private placement of 862,069 ordinary shares at $0.58 per share for $500,000 aggregate proceeds, executed pursuant to Regulation S. The Securities Purchase Agreement includes a 24-month lock-up on further issuances and registration statements, which is characteristic of dilutive equity financing. This unregistered sale of equity securities is material to investors assessing capital structure and ownership dilution.
View raw filing on EDGAR →The filing discloses multiple material events, but the dominant theme is substantial dilutive equity issuances. Item 3.02 reports unregistered sales of common stock totaling approximately 3.8 million shares issued to lenders and preferred stockholders (Streeterville and 1800 Diagonal) in conversion transactions and exchanges occurring June 15-17, 2026. Item 1.01 describes entry into three debt instruments (Quick Capital Note, 1800 Diagonal Note, and Streeterville exchanges) with conversion rights that trigger further dilution. While the filing also involves debt covenant obligations (Item 2.03), the primary disclosed activity centers on the issuance of unregistered equity securities as consideration for debt restructuring and preferred stock conversions, which is characteristic of dilutive_issuance events at small-cap issuers under financial stress.
View raw filing on EDGAR →The filing discloses a Stock Purchase Agreement (Item 1.01) under which NextNRG issued 260,000 shares of common stock to CEO Michael D. Farkas at $0.386 per share in exchange for debt forgiveness of $100,360. This is a dilutive equity issuance to an insider (the CEO and significant stockholder) in lieu of cash payment, which is a material capital structure event. The concurrent termination of the underlying promissory note (Item 1.02) confirms the debt-for-equity nature of the transaction.
View raw filing on EDGAR →Item 1.01 discloses a private placement of shares ("Shares") offered and issued under Section 4(a)(2) and Regulation D exemptions, with an Amendment No. 1 to Registration Rights Agreement dated June 18, 2026. The filing explicitly states the Shares were unregistered and issued without general solicitation, which is characteristic of a dilutive equity issuance. The forward-looking statements reference risks related to executing growth strategy and maintaining listing compliance, consistent with a capital raise by a smaller-cap company.
View raw filing on EDGAR →The filing discloses a completed public offering of 1,040,000 shares of common stock and 2,960,000 pre-funded warrants (exercisable for common stock) for aggregate gross proceeds of $3.2 million, consummated on June 16, 2026 under Item 1.01. The pre-funded warrants are immediately exercisable at $0.007 per share and represent substantial dilution to existing shareholders. This is a material equity issuance that would affect investor assessment of ownership and capital structure.
View raw filing on EDGAR →Bandwidth Inc. issued $316.25 million aggregate principal amount of 0% convertible senior notes due 2032 in a private placement under Rule 144A and Section 4(a)(2), with conversion into up to 5,986,169 shares of Class A common stock at an initial conversion price of approximately $72.64 per share, creating substantial dilution potential for existing shareholders.
View raw filing on EDGAR →New Mountain Finance Corp entered into a Seventh Supplement to its Note Purchase Agreement authorizing the issuance of $150 million in aggregate principal amount of senior notes ($40M Tranche A, $35M Tranche B, $75M Tranche C) in a private placement relying on Section 4(a)(2) of the Securities Act. The issuance will be used for general corporate purposes, investments, and debt repayment, materially increasing the Company's leverage.
View raw filing on EDGAR →Commercial Vehicle Group entered into a Capital on Demand™ Sales Agreement with JonesTrading to offer and sell up to $25 million of common stock "at the market" under Rule 415(a)(4). This is a registered direct offering of equity securities that creates potential dilution to existing shareholders. The $25 million offering size and the at-the-market structure are material to investors assessing capital structure and ownership dilution.
View raw filing on EDGAR →The filing discloses Item 3.02 (Unregistered Sales of Equity Securities) with a cross-reference to Item 8.01 for substantive details. Item 3.02 is the dedicated disclosure item for dilutive equity issuances such as private placements and PIPEs. While the actual transaction details are incorporated by reference to Item 8.01 (not shown in this excerpt), the presence of Item 3.02 itself signals an unregistered equity sale, which is material to investors as it affects share dilution and capital structure.
View raw filing on EDGAR →IIOT-OXYS entered into Amendment No. 1 to a Securities Purchase Agreement on June 12, 2026, authorizing issuance of up to 167 shares of Series D Convertible Preferred Stock, with a Third Additional Closing on June 16, 2026 issuing 30 shares (27 purchased + 3 as equity incentive) to accredited investor GHS under Section 4(a)(2) and Regulation D Rule 506(b). This unregistered private placement of preferred stock materially dilutes existing shareholders and affects the registrant's capital structure.
View raw filing on EDGAR →Tianci International consummated a registered public offering of 6,055,000 units (4,055,000 standard units and 2,000,000 pre-funded units) at $0.81 per unit on June 17, 2026, generating approximately $4.9 million in gross proceeds. Each unit includes common stock (or pre-funded warrant) and common warrants with anti-dilution provisions, materially diluting existing shareholders.
View raw filing on EDGAR →The filing discloses an At Market Issuance Sales Agreement (ATM) under which Sonoma Pharmaceuticals may offer and sell shares of common stock through an agent. The company has already sold 173,073 shares for $574,633 and increased the aggregate offering price to $3,641,703 as of the filing date. ATM offerings are classic dilutive equity issuances that signal capital-raising activity and potential shareholder dilution, material to investors assessing ownership stakes and capital structure.
View raw filing on EDGAR →Carlyle Credit Solutions completed an unregistered sale of 322,258 shares of Class I common stock for $5.9 million under Section 4(a)(2) and Regulation D exemptions, increasing outstanding shares from approximately 95.1 million to 95.4 million and materially affecting shareholder ownership and capital structure.
View raw filing on EDGAR →The filing's primary disclosure under Item 3.02 concerns the conversion of convertible promissory notes into common stock. Between June 12–17, 2026, holders converted approximately $663,188 of debt into 2,444,447 shares of common stock issued without Rule 144 restrictive legends. This represents a material dilutive issuance of equity securities that would affect a reasonable investor's assessment of ownership and capital structure, even though the conversions were pursuant to previously disclosed securities purchase agreements from 2025.
View raw filing on EDGAR →Blue Owl Real Estate Net Lease Trust sold 4,023,007 shares of Class I common shares for approximately $43.0 million in an unregistered offering exempt under Section 4(a)(2), Regulation D, and/or Regulation S.
View raw filing on EDGAR →Blue Owl Digital Infrastructure Trust sold 3,203,718 common shares across multiple classes for approximately $33.2 million in gross proceeds on June 1, 2026, pursuant to Section 4(a)(2), Regulation D, and/or Regulation S exemptions from registration under the Securities Act of 1933.
View raw filing on EDGAR →The filing discloses unregistered issuances of Common Stock on three dates (May 12, May 28, and June 15, 2026) totaling approximately 308,679 shares in exchange for redemptions of Series A1 and Series A Preferred Stock. The conversion prices declined sharply from $6.36 to $5.41 to $4.30 per share over the period, indicating deteriorating valuation. These are classic dilutive equity issuances that would materially affect shareholder ownership and are properly classified under Item 3.02.
View raw filing on EDGAR →Alvotech announced and priced a $152 million underwritten public offering of 22.67 million ordinary shares at $3.75 per share, concurrent with a private placement of 17.83 million shares to European investors at the same price. The combined offering raises approximately $152 million in gross proceeds and significantly increases share count, with proceeds intended for development, working capital, and potential debt repayment.
View raw filing on EDGAR →NeoGenomics disclosed the pricing of a convertible senior notes offering to qualified institutional buyers under Rule 144A. Convertible notes are inherently dilutive securities that can be converted into equity, making this a material capital-raising event that would affect investor assessment of share dilution and the company's financing strategy.
View raw filing on EDGAR →DUOS Technologies entered into an underwritten registered direct offering of 2,000,000 shares of common stock and 3,800,000 pre-funded warrants (exercisable at $0.001) for approximately $55 million in gross proceeds. The combination of a substantial equity issuance and highly dilutive pre-funded warrants represents a material capital raise that will significantly dilute existing shareholders.
View raw filing on EDGAR →Pubco completed an unregistered private placement sale of equity securities to the Foundation under Section 4(a)(2) of the Securities Act in connection with the business combination.
View raw filing on EDGAR →NOVONIX announced a material capital raising comprising an institutional placement of 129,334,163 ordinary shares at A$0.16 per share (a 31.2–33.3% discount to market prices) under ASX Listing Rule 7.1 placement capacity, together with a non-underwritten share purchase plan (SPP) offering up to 18,750,000 shares to eligible shareholders at the same price. The placement and SPP are expected to raise approximately A$23.7 million in aggregate, directed toward capital expenditure and production capacity expansion.
View raw filing on EDGAR →Smartbird amended its Securities Purchase Agreement to increase the aggregate principal amount of senior secured convertible notes from $50.0 million to $100.0 million, with conversion into Class A common stock at $4.00 per share, representing a material dilutive issuance of convertible securities.
View raw filing on EDGAR →The Company entered into an underwriting agreement on June 15, 2026, to offer and sell 14,000,000 shares of common stock through a forward sale mechanism, with an additional 2,100,000 shares subject to an underwriter option. This is a material equity issuance that will dilute existing shareholders. Although structured as a forward sale (with settlement expected by June 16, 2027), the Company will receive net proceeds and contribute them to its operating partnership for acquisitions and general corporate purposes, making this a dilutive capital raise transaction.
View raw filing on EDGAR →Magnachip entered into an At Market Issuance Sales Agreement (ATM) on June 17, 2026, authorizing the sale of up to $50 million in common stock shares through B. Riley Securities. ATM offerings are classic dilutive equity issuances that signal capital raising and potential shareholder dilution. The material nature is confirmed by the $50 million aggregate offering price and the company's stated use of proceeds for strategic growth initiatives in AI data centers and robotics.
View raw filing on EDGAR →The Company entered into a Securities Purchase Agreement to issue 15,000,000 shares of common stock for $3,750,000 in proceeds to three investors. This is a private placement of unregistered equity securities, which is a classic dilutive issuance event. The substantial share count and capital raise would materially affect a reasonable investor's assessment of ownership dilution and the company's financing strategy.
View raw filing on EDGAR →Collective Acquisition Corp. II completed unregistered sales of equity securities, including exercise of an over-allotment option generating $33 million in additional proceeds and a related private placement of $330 thousand, as part of the SPAC's IPO capitalization.
View raw filing on EDGAR →The Company amended pre-funded warrants originally issued in October 2025 to remove exercisability restrictions, enabling R01 Fund LP and Framework Ventures IV L.P. to exercise their warrants on a cashless basis, resulting in the issuance of an aggregate of 22,614,600 shares of Common Stock and increasing outstanding shares from approximately 27.8 million to 50.4 million shares.
View raw filing on EDGAR →SharonAI Holdings entered into Securities Purchase Agreements on June 17, 2026 for a private offering of approximately 6.7 million shares of Class A ordinary common stock at $68.73 per share, pre-funded warrants, and $600 million of 4.75% Convertible Senior Notes due 2032, generating approximately $1.5 billion in aggregate gross proceeds. The convertible notes are convertible into up to approximately 13.1 million shares of Common Stock at an initial conversion price of $95.66 per share. This is a material dilutive equity issuance raising substantial capital for the company's NVIDIA compute collaboration and AI Factory expansion.
View raw filing on EDGAR →Liberty Star entered into a Securities Purchase Agreement with 1800 Diagonal Lending LLC to issue a $73,700 convertible promissory note with 10% Original Issue Discount, convertible into common stock. This is a dilutive issuance of equity securities (via conversion rights embedded in the convertible note), a material financing event for a small-cap uranium exploration company that signals capital-raising pressure and future shareholder dilution.
View raw filing on EDGAR →XCF Global terminated a $50 million equity purchase agreement with Helena Global Investment Opportunities I LTD. that had reserved approximately 55 million shares for potential issuance. While the termination itself eliminates dilution risk, the core event disclosed is the unwinding of a dilutive equity arrangement that previously posed material overhang and dilution concerns. The filing emphasizes the reduction in "potential dilution and associated market overhang," indicating this was a material equity issuance arrangement.
View raw filing on EDGAR →The filing references a "Common Shares Purchase Agreement dated June 16, 2026" as Exhibit 10.1, which is the hallmark disclosure of a dilutive equity issuance. Although the Item 3.02 section itself is not provided in full, the exhibit and the boilerplate language disclaiming any offer to sell shares are consistent with a private placement or PIPE transaction. The presence of an executed purchase agreement for common shares indicates a material equity issuance that would dilute existing shareholders.
View raw filing on EDGAR →The filing discloses a firm commitment underwritten offering of 592,270 shares of common stock and 296,135 warrants, with gross proceeds of approximately $5.95 million (inclusive of over-allotment exercise). This is a registered equity issuance under an effective S-3 shelf registration statement, representing a dilutive capital raise material to investors' assessment of ownership and capital structure.
View raw filing on EDGAR →Dell disclosed the issuance of 3,438,364 shares of Class C common stock upon conversion of Class B common stock held by Silver Lake entities. While technically a conversion rather than a new issuance, this represents a dilutive equity event involving unregistered securities (relying on Section 3(a)(9) exemption) and a material change in the capital structure, with Class B shares declining from approximately 47.8M to 44.4M outstanding. The conversion by a significant shareholder (Silver Lake) is material to investors assessing ownership and control dynamics.
View raw filing on EDGAR →The filing discloses unregistered sales of Class C common stock on three dates (April 15, May 14, and June 12, 2026) totaling 573,657 shares for approximately $9.6 million in aggregate consideration. Item 3.02 specifically governs unregistered equity issuances, and the company explicitly states the sales were exempt under Section 4(a)(2) and Regulation S. This is a classic dilutive issuance that would materially affect a reasonable investor's assessment of share dilution and capital structure.
View raw filing on EDGAR →North Haven Net REIT sold an aggregate of 125,617 Class I shares and 15,966 Class F-I shares for approximately $2.94 million in total consideration to a feeder vehicle, with the sale exempt from registration under Section 4(a)(2) and Regulation D Rule 506. This is a classic unregistered private placement of equity securities, which Item 3.02 is designed to capture and which materially affects shareholder equity and ownership structure.
View raw filing on EDGAR →Isabella Bank Corporation entered into an Equity Distribution Agreement with Piper Sandler & Co. to issue and sell up to $30 million of common stock through an "at the market offering" under Rule 415. This is a dilutive equity issuance that would materially affect existing shareholders through potential dilution. The $30 million offering size and explicit authorization for ATM sales and private placements are hallmarks of a dilutive_issuance event.
View raw filing on EDGAR →